EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022

Date: December 28, 2012
Pages: 56
Price:
US$ 3,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E8330B4A44FEN
Leaflet:

Download PDF Leaflet

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022
EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022

Summary

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults (Fernandes de Abreu et al., 2009). In 2012, the US had the highest number of prevalent and incident cases among the 10 markets, and will continue to comprise the largest portion of the market until 2022. Western countries in the analysis had a higher number of prevalent cases in 2012 than did Asian countries (India, China, and Japan); however, this was not true for incident cases. In 2012, China had more incident cases than all countries except the US, and India had a higher number of incident cases than Italy, Spain, and Japan. The prevalence and incidence of MS vary greatly by age, gender, and geographical location. Regional differences in MS prevalence and incidence could be due to several factors including diagnostic criteria used, availability of medical technology, genetic and environmental risk factors, frequency of comorbidities, and population age and gender structure.

Scope
  • The Multiple Sclerosis EpiCast Report provide an overview of the risk factors and global trends of multiple sclerosis.
  • Data is provided for eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) in addition to emerging markets - India and China.
  • It includes a 10-year epidemiological forecast of multiple sclerosis prevalence and incidence segmented by gender, age (in five-year increments beginning at 20 years and ending at =85 years), and multiple sclerosis subtypes in 10 markets.
Reasons to buy
  • Develop business strategies by understanding the trends shaping and driving the global multiple sclerosis market.
  • Quantify patient populations in the global multiple sclerosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, gender, and subtypes that present the best opportunities for multiple sclerosis therapeutics in each of the markets covered.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Upcoming Related Reports

3 EPIDEMIOLOGY

3.1 Risk Factors
  3.1.1 Family members of MS patients have a 1%-5% risk of developing MS
  3.1.2 Women are twice as likely to develop MS, but men have a worse prognosis
  3.1.3 Caucasians have a higher risk of MS than any other race/ethnicity
  3.1.4 Protective effect of vitamin D on MS may relate to latitude and month of birth
  3.1.5 Timing of environmental exposures affects MS risk
  3.1.6 Exposure to smoking may increase MS risk and worsen prognosis
3.2 Comorbidities
  3.2.1 Autoimmune diseases may be comorbidities of MS
  3.2.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
3.3 Global Trends
  3.3.1 North America
  3.3.2 Europe
  3.3.3 Asia
3.4 Forecast Methodology
  3.4.1 Sources Used
  3.4.2 Forecast Assumptions and Methods
  3.4.3 Sources Not Used
3.5 Epidemiology Forecast of Multiple Sclerosis
  3.5.1 Total Prevalent Cases of Multiple Sclerosis
  3.5.2 Age-Specific Prevalent Cases of Multiple Sclerosis
  3.5.3 Gender-Specific Prevalent Cases of Multiple Sclerosis
  3.5.4 Total Incident Cases of Multiple Sclerosis
  3.5.5 Age-Specific Incident Cases of Multiple Sclerosis
  3.5.6 Gender-Specific Incident Cases of Multiple Sclerosis
  3.5.7 Multiple Sclerosis Subtypes
3.6 Discussion
  3.6.1 Conclusions on Epidemiological Trends
  3.6.2 Limitations of Analysis
  3.6.3 Strengths of Analysis

4 APPENDIX

4.1 Bibliography
4.2 About the Authors
  4.2.1 Epidemiologists
  4.2.2 Reviewers
  4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
  4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

LIST OF TABLES

Table 1: Sources of Prevalence and Incidence Data Used in the Epidemiology Forecast
Table 2: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ≥20, Male and Female, N, Select Years, 2012-2022
Table 3: 10 Markets, Prevalent Cases of Multiple Sclerosis, By Age*, Male and Female, N (Row %), 2012
Table 4: 10 Major Markets, Prevalent Cases of Multiple Sclerosis, Ages ≥20, By Gender, N (Row %), 2012
Table 5: 10 Markets, Incident Cases of Multiple Sclerosis, Ages ≥ 20, Male and Female, N, Select Years, 2012-2022
Table 6: 10 Markets, Incident Cases of Multiple Sclerosis, By Age*, Male and Female, N (Row %), 2012
Table 7: 10 Major Markets, Incident Cases of Multiple Sclerosis, By Gender, N (Row %), 2012

LIST OF FIGURES

Figure 1: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ≥20, Male and Female, N, Select Years, 2012-2022
Figure 2: 10 Markets, Prevalent Cases of Multiple Sclerosis, By Age*, Male and Female, N, 2012
Figure 3: 10 Markets, Prevalent Cases of Multiple Sclerosis, Ages ≥20, By Gender, N, 2012
Figure 4: 10 Markets, Incident Cases of Multiple Sclerosis, Ages ≥ 20, Male and Female, N, Select Years, 2012-2022
Figure 5: 10 Markets, Incident Cases of Multiple Sclerosis, By Age*, Male and Female, N, 2012
Figure 6: 10 Markets, Incident Cases of Multiple Sclerosis, By Gender, N, 2012
Figure 7: 10 Markets, Multiple Sclerosis Subtypes in Prevalent Cases, %*, 2012-2022

Ask Your Question

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: